id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-D-1038-0017,FDA,FDA-2012-D-1038,Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products; Availability,Notice,Notice of Availability,2013-11-25T05:00:00Z,2013,11,2013-11-25T05:00:00Z,,2013-11-26T13:43:05Z,2013-28173,0,0,0900006481495aaa
FDA-2012-D-1038-0018,FDA,FDA-2012-D-1038,Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products,Other,Guidance,2013-11-01T04:00:00Z,2013,11,2013-11-01T04:00:00Z,,2024-11-12T05:23:36Z,,1,0,0900006481498a25
FDA-2012-D-1038-0001,FDA,FDA-2012-D-1038,Draft Guidance for Industry; Availability: Preclinical Assessment of Investigational Cellular and Gene Therapy Products,Notice,Notice of Availability,2012-11-29T05:00:00Z,2012,11,2012-11-29T05:00:00Z,2012-02-28T04:59:59Z,2012-11-29T14:11:27Z,2012-28882,0,0,0900006481177429
FDA-2012-D-1038-0002,FDA,FDA-2012-D-1038,Draft Guidance for Industry; Preclinical Assessment of Investigational Cellular and Gene Therapy Products,Other,Guidance,2012-11-29T05:00:00Z,2012,11,2012-11-29T05:00:00Z,,2024-11-12T05:09:43Z,,1,0,09000064811775a5